HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Ocuphire Pharma (NASDAQ:OCUP) and maintained a $20 price target.
May 13, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating and a $20 price target on Ocuphire Pharma, indicating a positive outlook on the stock.
The reiteration of a Buy rating and a maintained price target of $20 by a reputable analyst firm like HC Wainwright & Co. suggests a strong conviction in the stock's potential. This endorsement could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100